It is time to change the paradigm by considering immunotherapy as essential part of cancer treatment. As you know, PD-L1 and other immune checkpoint inhibitors are of the new and promising pillars of cancer treatments. These treatments are agnostic of the type of cancer disease, even if they are more efficient in melanoma and nonsmall cell cancer than in colorectal cancer, but in some way, they can work in any type of cancer as far as the disease is immune hot. We have to acknowledge that immunotherapy treatments can dramatically change the outcome for a subpopulation of patients with improved response rate and prolonged overall survival. Interestingly, the “tail of the curve” is flat and corresponds to a percent of patient which will survive for many years. However, we have to acknowledge that this tail of the curve is at maximum 20 to 30% of the cancer population, and we have to improve the global outcomes of cancer, namely, in the subpopulation of patients which does not respond to immunotherapies.

To improve efficacy, several combinations have been evaluated, including combination of PD-1, PD-L1 with vascular endothelial growth factor (VEGF) inhibitors, chemotherapy, CTLA-4 checkpoint inhibitors, so a lot of these combinations are under investigation. For example, atezolizumab + bevacizumab was demonstrated to be superior to sorafenib for advanced hepatocellular carcinoma in the Imbrave150 study and is today the standard of care. Combination of PD-L1 inhibitors with chemotherapy in head and neck squamous cell carcinoma (HNSCC) have demonstrated 44% response rate that compares favorably with pembrolizumab alone with 20%, while chemotherapy demonstrated 40% response rate, but it is noteworthy that the duration of response for pembrolizumab alone is longer than chemo alone or combination, with chemotherapy possibly altering immune cells which does not aid in prolonged response.

Combination of two different checkpoints, inhibitor PD-1 plus CTL-A4, comes at the cost of increased toxicity from 27 to 60%.

The concept of human intratumoral immunotherapy involves producing a local priming of tumor, with intratumoral injection of different compounds along with the expectation of on-tumor effects, which will be distant from the site of injection. Such in situ immunization has major advantages over cancer vaccine, that is, a one off-the-shelf product that might fit all patients, which avoids tumor sampling and patient per patient tumor vaccine harvesting.

A comparison of intratumoral versus intravenous administration of ipilimumab in combination with systemic administration of nivolumab in patients with metastatic melanomas is under evaluation (NCT028575669). Intratumoral administration of toll-like receptors (TLR)3, 4, 7/8 and 9 agonists is under evaluation for the treatment of solid and hematologic malignancies. Immunomodulation with an oncolytic peptide LTX-315, which induces a malignant cell death and elicits anticancer immune responses, has been demonstrated to rapidly reprogram the tumor microenvironment (NCT01986426). Recently, an oncolytic virus, talimogene laherparepvec (T-VEC), has been approved by the Food and Drugs Administration (FDA) for the treatment of unresectable cutaneous, subcutaneous, and nodal lesions in patients with recurrent melanoma after initial surgery. Recently, T-VEC has demonstrated a tolerable safety profile with ipilimumab, and the combination appeared to have greater efficacy than either T-VEC or ipilimumab monotherapy. Its added value when used in combination with anti-PD-1 is currently being tested in a randomized phase 3 study (NCT02263508).
Interventional radiologists have to be part of this research, because they are the best qualified for providing safe, accurate tumoral injections, ideally under image guidance. They can help to answer many unsolved questions such as: Does some tumor location need to be prioritized for injection because of better outcomes? What is the ideal imaging for targeting active tumor cells and the microenvironment while avoiding necrosis? Today, most of the target lesions will have to be injected several times over a few months and, as interventional radiologists (IRs), we must select the adequate target and search for possible delivery platforms. Technical aspects such as needle size, needle type (end hole, side all, etc.) are controlled by IRs and also need research.8

Close collaboration between medical oncologists, diagnostic radiologists, IRs, and planning nurses are key to successful implementation of intratumoral immunotherapy trials and clinical practice, to the point that a multidisciplinary tumor board dedicated to this practice is recommended.9

Many questions remain to be answered, and IRs must be part of this research: dose by body weight versus dose per tumor? small volume versus large volumes? Where is the drug effectively delivered? Does it stay within the tumor? How long? Do we need X-ray visible drug? Do we need delivery platform, as suggested by early animal experiment?2,9,10,11 IRs must investigate other intratumoral routes such as intralymphatic and intra-arterial. Maybe in the future, we can inject in size of the particle theory. There are many options that we have to embrace, and we have to be part of this broad delivery story for immune-oncology.

Finally, as diagnostic radiologists, we need to thoroughly evaluate intratumoral immunotherapy, as separately evaluating the injected lesions and not-injected lesions distant from the location of injection is a major point. We need to better understand our new treatment, and realize that response evaluation criteria in solid tumors (RECIST) system is not enough when dealing with local therapy, with the potential of a global effect. Intratumoral RECIST, called itRECIST, criteria have been recently reported and need to be applied.12

Both interventional oncology and immuno-oncology use the same abbreviation IO. It is important that both IOs can collaborate in research to provide the best to our patients.

Conflict of Interest
Dr. de Baere reports personal fees from Guerbet, and grants and personal fees from Terumo, outside the submitted work.

References